Our results confirm the oncogenic role of KDM4C: the MSKCC database indicates that its expression increases with tumor stage, while Oncomine data identify a significant KDM4C overexpression in PCa vs. normal prostate gland (Figure 2) and in grade 3 vs. grade 2 PCa (p = 0.002, fold change 13.125, data not shown). This evidence concerns the gene KDM4C and posterior cortical atrophy.